


Drug Development Profiles in Cortellis

This guide explains where to find objective overviews summarizing important events in the development of a drug.

The Drug Development Profile in Cortellis Competitive Intelligence provides the history of a drug written by the editorial team. It includes important highlights from the drug's development such as licensing agreements, planned clinical trials, updates for the approval process, applications for regulatory designations and other news from conferences, literature, press releases and other sources.

Example: Identify the latest milestone reached by *elraglusib*.

1. Quick search the drug name at the top and select '**Index**'.




2. Click the **drug name** in the results table.

Results		Per page: 25	Sort by: Relevance	Order Columns		View	
✓	Drug Name	Active Companies	Active Indications	Target-based Actions	Highest Status	Technologies	
		Filters : [0]	Filters : [0]	Filters : [0]	Filters : [0]	Filters : [0]	
✓	elraglusib	Actuate Therapeutics	Adenocarcinoma; Adenoid tumor; Bladder cancer; Bone tumor; Brain tumor; Breast tumor; Cancer; Colorectal tumor; Glioblastoma; Hematological neoplasm; Lung tumor; Lymphoma; Melanoma; Meningioma;	Glycogen synthase kinase-3 beta inhibitor	Phase 2 Clinical	Infusion; Intravenous formulation; Small molecule therapeutic	

3. Go to 'Development Profile' tab.

'Development Profile' is available for all drugs in Cortellis. The 'Summary' at the top provides an overview highlighting names of companies involved in the development of the drug, the mechanism of action and indications tested in clinical trials.



elraglusib

Snapshot Highlight ☐ Search Terms & Synonyms < Previous Next >

Latest Press Releases

Latest Event Transcripts

Broker Research Reports

Development Profile

- Summary
- Patents & Generics
- Regulatory
- Postmarketing
- Premarketing


DEVELOPMENT PROFILE

New Content: Highlight Off

Summary

[Actuate Therapeutics](#), based on technology discovered at [University of Illinois](#) and [Northwestern University Feinberg School of Medicine](#), is developing elraglusib (9-ING-41), the lead from a program of maleimide-based GSK-3 beta inhibitors, including 9-ING-87, for the potential iv treatment of solid tumors including ovarian cancer, colorectal cancer, lung cancer, prostate cancer, bladder cancer, breast cancer, glioblastoma, neuroblastoma, pancreatic cancer, bone cancer, sarcoma, renal cancer and thyroid cancer, salivary gland cancer, adenoid cystic carcinoma and for hematological malignancies including lymphoma. The company is also investigating the drug for the potential treatment of myelofibrosis, pediatric brain tumor, pediatric meningioma, melanoma and also for osteosarcoma, histiocytoma, angiosarcoma, fibrosarcoma, liposarcoma, leiomyosarcoma, rhabdomyosarcoma, soft tissue, Ewing sarcoma and metastatic pancreatic adenocarcinoma [[1649602](#)], [[1653909](#)], [[1653910](#)], [[1753998](#)], [[1868726](#)], [[1957417](#)], [[2075626](#)], [[2218080](#)], [[2239640](#)], [[2283808](#)], [[2434562](#)], [[2465389](#)], [[2554266](#)]. In September 2021, a phase II trial of 9-ING-41 plus carboplatin in patients with advanced, metastatic salivary gland carcinoma and adenoid cystic carcinoma was begun [[2434562](#)]. In January 2022, a phase II study (RiLEY) of 9-ING-41, combined with retifanlimab plus gemcitabine/nab-paclitaxel as frontline therapy for patients with advanced pancreatic adenocarcinoma was initiated [[2616829](#)]. In February 2022, a phase II study of 9-ING-41 plus FOLFIRINOX alone or with losartan was initiated [[2610361](#)]. In December 2018, a phase I/II trial for refractory hematological malignancies and solid tumors was initiated [[2075626](#)]. In June 2020, a phase I trial was initiated for refractory pediatric cancer, pediatric brain tumor, neuroblastoma recurrent, pediatric lymphoma and pediatric meningioma [[2239640](#)]. In October 2017, a phase II trial was planned in children with neuroblastoma [[2009766](#)]. In November 2019, a phase II trial for myelofibrosis was planned in 2020 [[2218080](#)].

4. Bookmarks on the left help you quickly navigate to other sections. For example, click 'Regulatory' to read information related to regulatory authorities.



Development Profile

- Summary
- Patents & Generics
- Regulatory**
- Postmarketing

Regulatory

THE US

In July 2023, the US FDA granted Orphan Drug designation to elraglusib for the treatment of pancreatic cancer [[3022769](#)].

In January 2018, the company filed two Fast Track designation applications for the drug for glioblastoma and neuroblastoma [[2009773](#)].

In March 2016, the US FDA granted 9-ING-41 Orphan designation for the treatment of glioblastoma [[1748013](#)]. In August 2017, 9-ING-41 was granted Orphan designation for treatment of neuroblastoma [[1957417](#)]. In October 2017, the US FDA granted Rare Pediatric Disease designation for 9-ING-41 for the treatment of neuroblastoma [[2009766](#)].

OTHER PUBLICATION

2023 July 18
FDA Orphan Drug Designations and Approvals:
elraglusib; Treatment of pancreatic cancer
Internet site
Food and Drug Administration
Source ID: 3022769

The latest news about *elraglusib* as of July 2023 was the Orphan Designation being granted for pancreatic cancer in the US. You can navigate to this drug report by clicking [this link](#).

5. If a drug has been discontinued or stopped development, the 'Summary' section will provide a reason for discontinuation if disclosed. Alternatively, a comment will be added explaining that no news has been reported for a period of time and therefore the drug is presumed to be NDR (No Development Reported).

Here is an example of a discontinued drug in Cortellis.

To find out what's included in your subscription, contact your Clarivate account manager or **LS Product Support**.